



Medicine: lenvatinib (brand name: Kisplyx[®]) for advanced renal cell carcinoma

Eisai Ltd

What is lenvatinib used for?

Lenvatinib was considered for use together with another medicine, called everolimus to treat renal cell carcinoma (RCC), which is the most common type of kidney cancer in adults. It starts in the lining of tubes in the kidneys that are involved in filtering the blood and making urine. In advanced RCC the cancer has spread beyond the kidneys to other parts of the body. Lenvatinib is used together with everolimus, to treat adults who have advanced RCC and who have already received a type of treatment called a vascular endothelial growth factor (VEGF) targeted therapy.

How does lenvatinib work?

Lenvatinib is a medicine called a tyrosine kinase inhibitor. It works by blocking the activity of proteins called receptor tyrosine kinases (RTKs). RTKs are involved in cancer cell growth and in the development of new blood vessels that supply cancer cells with nutrients and oxygen. By blocking these proteins, lenvatinib can help slow the growth and spread of the cancer.

What has SMC said?

SMC has accepted lenvatinib for the treatment of adults with advanced renal cell carcinoma as described above.



Why has SMC said this?

SMC looks at how well new medicines work compared with current treatments available in Scotland and in relation to how much they will cost to buy and administer (for example, if the medicine has to be given at a clinic or side effects have to be monitored).

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland. When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

To do this SMC consider the following:

- Clinical trial and economic evidence from the company that makes the medicine.

- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.
- Information from patient groups about the potential impact of the medicine on patients and carers.

After careful consideration, applying extra flexibility because lenvatinib is a medicine for a rare, end of life condition and after receiving a confidential discount from the company, SMC was able to accept it as a possible treatment within NHS Scotland.

What does SMC's decision mean for me?

If your healthcare professional thinks that lenvatinib for use as described above is the right medicine for you, you should be able to have your treatment on the NHS in Scotland. For further information see:

Medicines in Scotland: What's the right treatment for me?

www.healthcareimprovementscotland.org/medicinesbooklet.aspx



More information

The organisations below can provide more information and support for people with kidney cancer and their families. SMC is not responsible for the content of any information provided by external organisations.

Kidney Cancer Scotland



<https://www.kcuk.org.uk/scotland/>



0141 428 3494

Kidney Cancer Support Network



<http://www.kcsn.org.uk>



01209 890326

Kidney Research UK



<http://www.kidneyresearchuk.org>



0300 303 1100

You can find out more about lenvatinib (Kisplyx) in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<http://www.ema.europa.eu>

Date advice published: 11 November 2019

SMC No: (SMC2199)